Biotechnology News and Research

RSS

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

Rubicon Genomics, Inc., a developer of pre-analytical amplification products that enable more comprehensive genetic analysis of clinical and research samples, announced today that it has reached agreement with ZyGEM to non-exclusively market Rubicon's PicoPlex™ single-cell amplification kits in Australia and New Zealand.

30 Jan 2010

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.

29 Jan 2010

LinkMed’s portfolio company receives order from Siemens AG for DIGNITY Carrier

LinkMed’s portfolio company has received an order from Siemens AG, Health Care Sector, Germany for its patient transportation solution, DIGNITY™ Carrier, for setting up patients for PET/CT imaging for special applications.

29 Jan 2010

Hitachi High-Technologies to begin shipment of Tabletop Microscope TM3000 from April

Hitachi High-Technologies Corporation today announced the development of the Tabletop Microscope TM3000. Shipments of the compact, affordably priced, and exceptionally user-friendly TM3000 are scheduled to start on April 1, 2010.

29 Jan 2010

Pretreating BPA plastic may be the key to dispose waste in an eco-friendly way

Just as cooking helps people digest food, pretreating polycarbonate plastic - source of a huge environmental headache because of its bisphenol A (BPA) content - may be the key to disposing of the waste in an eco-friendly way, scientists have found. Their new study is in ACS' Biomacromolecules, a monthly journal.

29 Jan 2010

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

The treatment of illness has traditionally been based on the law of averages – what works best for the largest number of patients. As a result, billions of dollars are spent every year on treatments that could be ineffective or even harmful for some patients. What if doctors could tell with a simple test which course of treatment would be best for a particular patient?

From QIAGEN Manchester Limited 29 Jan 2010

Genzyme implements new annual and long-term incentive plans for senior executives

Genzyme Corporation announced today that it has adopted new annual and long-term incentive plans for senior executives that will be utilized beginning in 2010.

29 Jan 2010

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA’s pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyra™.

29 Jan 2010

Life Technologies collaborates with Ignite Institute to create genomic sequencing center

Life Technologies Corporation and the Ignite Institute for Individualized Health announced today a collaboration to create a ground-breaking genomic sequencing center at Ignite’s new facility in Northern Virginia.

28 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Life Technologies Corporation today announced results for its fourth quarter and full year ending December 31, 2009. Non-GAAP revenue for the fourth quarter was $874 million, resulting in full year non-GAAP revenues of $3.30 billion, an increase of 5 percent over the $3.14 billion reported for 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 28 Jan 2010

Cenduit announces strategic business alliance with invivodata

Cenduit, LLC, and invivodata, inc., today announce a strategic business alliance to further improve clinical trial efficiencies by adding the scientific and operational benefits of invivodata’s electronic Patient Reported Outcomes (ePRO) solutions to the proven efficiencies of Cenduit‘s Interactive Response Technology solution (IRT).

28 Jan 2010

Baxter International reports net income of $572M for the fourth-quarter of 2009

Baxter International Inc. today reported strong performance for the fourth quarter of 2009, and provided its financial outlook for the first quarter and full-year 2010.

From Baxter International Inc. 28 Jan 2010

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Repligen Corporation announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical. Repligen is the world's leading supplier of recombinant Protein A and has manufactured recombinant Protein A for GE Healthcare for more than 10 years.

28 Jan 2010

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

Formatech continues its pledge to give back and make a difference in the biotechnology and pharmaceutical community with its Fillanthropy Program. Since the program’s inception, Formatech has donated $308K in aseptic liquid fill and finish manufacturing services to companies developing new drug therapies.

28 Jan 2010

New insight into reprogramming of cells

A discovery by Babraham scientists brings new insight into how cells are reprogrammed and a greater understanding of how the environment, or factors like nutritional signals, can interact with our genes to affect health. As an embryo develops, cells acquire a particular fate, for example becoming a nerve or skin cell. The findings, reported online in the journal Nature, pinpoint a protein called AID as being important for complete cellular reprogramming in mammals.

28 Jan 2010

New research findings may lead to new treatment options for abdominal aortic aneurysms

New research findings from a team at the Providence Heart + Lung Institute at St. Paul's Hospital and the University of British Columbia (UBC) may lead to new treatment options for abdominal aortic aneurysms (AAA) - a potentially fatal disease that currently has no pharmacological treatments.

28 Jan 2010

Life Technologies announces a series of investments and new technologies for genetic sequencing research

Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, today announced a series of investments and new technologies designed to extend the use of sequencing in the research arena and make it more relevant for physicians.

28 Jan 2010

Biotechnology News and Research

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

LinkMed’s portfolio company receives order from Siemens AG for DIGNITY Carrier

Hitachi High-Technologies to begin shipment of Tabletop Microscope TM3000 from April

Pretreating BPA plastic may be the key to dispose waste in an eco-friendly way

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

Genzyme implements new annual and long-term incentive plans for senior executives

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Life Technologies collaborates with Ignite Institute to create genomic sequencing center

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Cenduit announces strategic business alliance with invivodata

Baxter International reports net income of $572M for the fourth-quarter of 2009

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

New insight into reprogramming of cells

New research findings may lead to new treatment options for abdominal aortic aneurysms

Life Technologies announces a series of investments and new technologies for genetic sequencing research

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News